Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Methicillin-Resistant Staphyloccocus Aureus (MRSA) | Unmet Need | Bone and Joint infections | US/EU | 2017

Login to access report north_east
Contact sales account_box

Adult OM/PJI due to MRSA are among the most hard-to-treat MRSA infections due to the difficulties for the body’s natural infection-fighting cells and antibiotics to reach the infected tissues in the bones. However, there is no guidance published by the FDA or the EMA to help drug developers to design clinical trials testing antibiotics for OM/PJI. Indeed, no new antibiotic has been approved for the treatment of OM/PJI by the FDA or EMA in the last two decade, and only a few clinical trials have been conducted to evaluate antibiotics’ efficacy and safety/tolerability for OM/PJI. The lack of approved labels and the paucity of relevant clinical efficacy and safety data force managing physicians to rely on their own experience to select antibiotics for a protracted therapy required for adult OM/PJI due to MRSA, representing a significant unmet need in this field.

Questions answered:

  • What are the treatment drivers and goals for adult OM/PJI due to MRSA?
  • What attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for adult OM/PJI due to MRSA?
  • What are the prevailing areas of unmet need and opportunity in adult OM/PJI due to MRSA?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European ID specialists for a hypothetical new drug for adult OM/PJI due to MRSA?

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 31 European ID specialists fielded in January 2017

Key companies: Allergan, Cempra, Merck, Pfizer

Key drugs: vancomycin, daptomycin, dalbavancin, linezolid, ceftaroline, Taksta, rifampin, TMP/SMX

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)
Hyperkalemia is a potentially life-threatening condition characterized by a serum potassium concentration that exceeds 5.5 mEq/L. Despite various guidelines, a universally accepted consensus on the…
north_east
Report
Primary Biliary Cholangitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Primary Biliary Cholangitis (US)
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation and progressive damage to intrahepatic bile ducts, leading to bile buildup, followed by…
north_east
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
north_east
Report
Systemic Lupus Erythematosus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Systemic Lupus Erythematosus (US)
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems. SLE symptoms range from general malaise to serious CNS and renal manifestations. Hydroxychloroquine…
north_east
Report
Chimeric Antigen Receptor (CAR) T-Cell Therapy – Access & Reimbursement – Access & Reimbursement – Chimeric Antigen Receptor (CAR) T-Cell Therapy (US)
Ever since Novartis’s Kymriah became the first chimeric antigen receptor (CAR) T-cell therapy approved by the FDA for a cancer indication (acute lymphoblastic leukemia) in 2017, this class of…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east